This “Sciatica - Pipeline Insight, 2020” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Sciatica pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
Global coverage
Sciatica Understanding

Sciatica: Overview

Sciatica is a debilitating condition in which the patient experiences pain and/or paresthesias in the distribution of the sciatic nerve or an associated lumbosacral nerve root. Often, a common mistake is referring to any low back pain or radicular leg pain as sciatica. Sciatica is specific to the pain that is a direct result of sciatic nerve or sciatic nerve root pathology. The sciatic nerve is made up of the L4 through S2 nerve roots which coalesce at the pelvis to form the sciatic nerve. At up to 2 cm in diameter, the sciatic nerve is easily the largest nerve in the body. Sciatica pain often is worsened with flexion of the lumbar spine, twisting, bending, or coughing. The sciatic nerve provides direct motor function to the hamstrings, lower extremity adductors, and indirect motor function to the calf muscles, anterior lower leg muscles, and some intrinsic foot muscles. Also, indirectly through its terminal branches, the sciatic nerve provides sensation to the posterior and lateral lower leg as well as the plantar foot. It is an important distinction to know that most cases of sciatica result from an inflammatory condition leading to an irritation of the sciatic nerve. Conversely, direct compression of the nerve leads to more severe motor dysfunction which is often not seen, and if present, would warrant a more meticulous and expeditious workup.

Symptoms

Common Sciatica Symptoms include:
Pain
Weakness
Numbness, tingling, and/or a pins-and-needles sensation
Change in posture may aggravate or relieve pain
Diagnosis

Sciatica is a clinical diagnosis, and therefore, a thorough history and physical examination are necessary for a complete evaluation and diagnosis. Imaging is initially of little value. If warranted, plain films of the lumbosacral spine may evaluate for fracture or spondylolisthesis. Noncontrast CT scan may be performed to evaluate fracture if plain films are negative. Additionally, pain that has been persistent for 6 to 8 weeks and not responding to conservative management should be imaged. In this case, MRI is the imaging modality of choice. In cases where the neurologic deficit is the present or mass effect is suspected, immediate MRI is the standard of care in establishing the cause of the pain and ruling out pressing surgical pathology.

Treatment

It involves medical therapies such as:
A short course of oral NSAIDs
Opioid and nonopioid analgesics
Muscle relaxants
Anticonvulsants for neurogenic pain
In the event oral NSAIDs are insufficient, a course of oral corticosteroids may be beneficial
Localized corticosteroid injections
Deep tissue massage may be helpful
Surgical evaluation and correction of any structural abnormalities such as disc herniation, epidural hematoma, epidural abscess or tumor
Sciatica Emerging Drugs Chapters

This segment of the Sciatica report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Sciatica Emerging Drugs

Semdexa: Scilex Pharmaceuticals

Semdexa is being developed by Scilex Pharmaceuticals for the treatment of sciatica. It is non-opioid injectable therapeutic on track to be the first and only FDA-approved epidural steroid product. It is currently in phase III stage of development.

KLS 2031: Kolon Life Science

KLS 2031 is being developed by Kolon Life Science for the treatment of Sciatica. It blocks pain signal delivered in the brain and improves pain environment. It is currently in phase I/IIa stage of development.

SR 419: SIMR (Australia) Biotech Pty Ltd

SR 419 is being developed by SIMR (Australia) Biotech Pty Ltd for the treatment of Unilateral Sciatica. The company is currently evaluating the efficacy, safety, tolerability, and pharmacokinetics of SR419 in participants with neuropathic pain due to Postherpetic Neuralgia, Diabetic Peripheral Neuropathy, or Unilateral Sciatica. It is currently in phase I stage of development.

Sciatica: Therapeutic Assessment

This segment of the report provides insights about the different Sciatica drugs segregated based on following parameters that define the scope of the report.

Major Players in Sciatica

There are approx. 10+ key companies which are developing the therapies for Sciatica. The companies which have their Sciatica drug candidates in the most advanced stage, i.e. phase III include Scilex Pharmaceuticals and others.

Phases

This report covers around 10+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage products (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Sciatica pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Infusion
Intradermal
Intramuscular
Intranasal
Intravenous
Oral
Parenteral
Subcutaneous.
Molecule Type
Products have been categorized under various Molecule types such as
Gene therapies
Small molecule
Vaccines
Polymers
Peptides
Monoclonal antibodies
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Sciatica: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Sciatica therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sciatica drugs.

Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Sciatica R&D. The therapies under development are focused on novel approaches to treat/improve Sciatica.
In March 2019, Sorrento Therapeutics stated that its majority owned subsidiary Scilex Pharmaceuticals has closed a transaction to merge with Mountain View, California, based Semnur Pharmaceuticals, Inc. (Semnur) to form a new company, Scilex Holding Company (Scilex Holding).
Sciatica Report Insights
Sciatica Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs
Sciatica Report Assessment
Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs
Key Questions

Current Treatment Scenario and Emerging Therapies:
How many companies are developing Sciatica drugs?
How many Sciatica drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Sciatica?
What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Sciatica therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Sciatica and their status?
What are the key designations that have been granted to the emerging drugs?
Key Players
Breath of Life International Pharma
Biogen
Renovis
Regeneron Pharmaceuticals
SIMR (Australia) Biotech Pty Ltd
Cephalon
Semnur Pharmaceuticals
Key Products
BOL-DP-o-04 + SCO
BG00010
REN-1654
REGN475
SR419
CEP-37247
SP-102